108 articles - From Friday Oct 03 2025 to Friday Oct 10 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Hepatology |
|---|
| Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.
PPAR agonists are effective second-line therapies for primary biliary cholangitis. Treatment ranking differences likely reflect variations in outcomes, populations, and drug mechanisms. In the absence of head-to-head trials, network meta-analysis provides important insights into comparative effectiveness. Further studies are warranted to confirm long-term safety and improve the evaluation of patient-centered outcomes. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression.
Our study reveals that gut microbiota dysbiosis is implicated in CPH progression, potentially providing new avenues for microbiome-based treatment for CPH. |
| Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study.
Empirical donor selection and a two-dose capsule FMT regimen improved clinical outcomes in a large-scale system treating patients with CDI. |
| Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.
Approximately one in five people with Rome IV IBS used opioids on a regular basis. Compared with non-users, opioid users had worse QoL, greater psychological impairment, and higher direct healthcare costs. |
| Clin Gastroenterol Hepatol |
| Associations Between Sexual Orientation and Disorders of Gut-Brain Interaction in Sexual Minority Populations.
Sexual orientation was independently associated with DGBI diagnoses among men, with no significant associations observed among women. These findings underscore the importance of considering gender-specific patterns when evaluating gastrointestinal health in sexual minority populations and highlight the need for tailored, inclusive approaches to DGBI care and research. |
| EUS-GUIDED LIVER BIOPSY AND PORTAL PRESSURE MEASUREMENT COMPARED TO TRANSJUGULAR APPROACH: A RANDOMIZED CONTROLLED TRIAL.
EUS is superior to TJ for simultaneous acquisition of adequate LB and reliable PPG, suggesting it has an important role in evaluating chronic liver diseases. |
| Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis.
Patients with EoE treated with dupilumab were able to safely reintroduce EoE trigger foods into their diet without exacerbation of histologic, endoscopic, or symptomatic measures of EoE severity. Some patients were able to reintroduce food at an earlier timepoint than others. , Number NCT05247866. |
| Even Lower Alcohol Intake Might Be Harmful For East Asian Males With MASLD Spectrum.
East Asian men with MASLD had increased LRE risk at thresholds substantially. |
| From Pixels to Peristalsis: Comparing Achalasia Diagnosis with Artificial Intelligence to Expert Endoscopists.
These results indicate that AI can leverage upper endoscopy videos to detect achalasia with an accuracy comparable to that of expert endoscopists. |
| OCCASIONAL CONSTIPATION: PREVALENCE AND IMPACT IN THE ROME IV GLOBAL EPIDEMIOLOGY STUDY.
Rome-defined OC is common on a global scale, associated with psychological distress, reduced QoL, other Rome IV diagnoses, and high healthcare utilization. |
| Resolution of metabolic dysfunction improves liver health among Chinese children: evidence from two prospective cohorts.
Metabolic dysfunction is a strong predictor of incident hepatic steatosis in children, and resolution of this dysfunction attenuates the attendant risk. These findings highlight the importance of primary and secondary interventions targeting metabolic risk factors to improve liver health in children. |
| Endosc Int Open |
| Anti-reflux barrier competency can be estimated by gastric folds stretching during intragastric insufflation without special equipment.
Flattening of gastric folds or mucosal ridges during insufflation is a reliable predictor of IGP. This finding may help identify patients with anti-reflux barrier dysfunction during regular endoscopic examination. |
| Post-endoscopy esophageal adenocarcinoma and root cause analysis in Auckland, New Zealand.
Auckland's PEEC prevalence aligns with international post-endoscopy upper gastrointestinal cancer rates. Root-cause analysis underscores that a significant proportion of PEECs may be preventable with improved clinical practice. |
| Endoscopy |
| Environmental Impact of Computer-Aided Diagnosis in Colonoscopy: A Carbon Footprint Assessment of a Prospective Study Cohort.
Using CADx in the leave-in-situ strategy would increase the environmental burden of colonoscopy. |
| Greener Colonoscopy: CO2 emissions are reduced by 87% with judicious CO2 use and adoption of a non-leak gas/water valve.
Judicious CO2 use and adoption of a non-leak valve significantly reduces CO2 emissions and costs in colonoscopy, contributing to the NHS's goal of delivering a "net zero" service. We suggest turning off CO2 when not needed, adopting non-leak valves, implementing this practice in other endoscopic procedures and encouraging al endoscope manufacturers to develop similar valves. |
| Gut |
| Asian Pacific Association of Gastroenterology task force recommendations on surveillance for <i>Helicobacter pylori</i> associated gastric premalignant conditions.
These statements aim to provide a structured, evidence based surveillance framework for clinical practice in the Asia Pacific region, while also identifying priority areas for future research. |
| Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α-IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers.
Our findings identify the crosstalk between LSECs and hepatocytes in aged livers aggravating HIRI via MEIS2/IL-1α/IL1R1/TNF-α axis, suggesting that IL-1α neutralising antibody can be exploited as a promising therapeutic strategy for aged HIRI. |
| DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease.
These findings demonstrated that sitagliptin alleviated α-synuclein deposition in the gut and brain through modulation of TLR2-mediated inflammation and altered the gut microbiome composition towards a more favourable profile, which indicates that DPP-4is can offer a novel therapeutic avenue for managing PD. |
| Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma.
Activation of the galectin-4/LDHA/HIF-1α and CXCL6 axis plays a pivotal role in ATZ/BVZ therapy resistance. Galectin-4 serves as a promising therapeutic target to improve immunotherapy efficacy and an effective predictive biomarker for immunotherapy response in HCC. |
| Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates <i>ZFP36L2</i> as a driver gene for pancreatic ductal adenocarcinoma.
Chromatin interaction analysis identified 416 potential target genes and MPRA revealed 178 NCSMs impacting reporter activity (19.45% of those tested). Targeted luciferase validation confirmed negative effects on gene regulatory activity for NCSMs near as a novel PDAC driver gene with a likely tumour suppressor function. |
| Single-cell analysis identifies RETN<sup>+</sup> monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure.
RETN + monocytes constitute a distinct immunoregulatory subset enriched in HBV-ACLF, and their product, Resistin, exerts significant hepatoprotective and anti-inflammatory effects. These findings highlight RETN + monocytes and Resistin as promising immunotherapeutic targets for HBV-ACLF. |
| Hepatology |
| Association between longitudinal weight change and clinical outcome in individuals with MASLD.
In MASLD, weight gain is associated with increased LREs risks and liver stiffness progression. Conversely, weight loss confers benefits for liver stiffness improvement and modifies LREs risk in those who achieve obesity reversal. |
| Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p - pyroptosis axis.
HepEVs-derived miRNAs, particularly miR-153-3p, contribute to endothelial dysfunction in CLD by triggering pyroptosis through a paracrine mechanism. Inhibiting Caspase-1 may provide a novel therapeutic approach to mitigate endothelial dysfunction in CLD. |
| Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma.
Our findings emphasize the therapeutic potential of combining nanotechnology and immunotherapy to reshape the TME and overcome immunotherapy resistance in fibrotic tumors, such as CCA. Targeting both ECM and immune checkpoints has emerged as a promising and versatile strategy to enhance the efficacy of immunotherapy against desmoplastic cancers. |
| Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.
In addition, several novel immunotherapeutic targets have been identified and treatments exploiting those targets are currently at early as well as late stages of clinical development. Herein, we review this evolution of immunotherapy for HCC which holds the potential for increasing therapeutic precision and thus for maximizing the benefit of patients while simultaneously reducing their risk of harm. |
| Sarcoid liver disease - A review article.
Patients with ongoing hepatic inflammation require the initiation of the disease-modifying agents to prevent fibrosis and decompensation. This review article summarizes the existing literature on etiology, risk factors, pathogenesis, clinical features, and the management of hepatic sarcoid. |
| Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.
SOAT1 functions as both a metabolic vulnerability and an immune regulator in HCC. Its inhibition disrupts tumor-promoting metabolic processes while enhancing immune activation, presenting it as a promising therapeutic target. Combining SOAT1 inhibition with PD-1 blockade holds potential for improving outcomes in HCC immunotherapy. |
| J Hepatol |
| HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.
In a phase 3 biomarker validation study, HES V2.0 had higher sensitivity than ASAP for HCC detection, and a similar or higher sensitivity than GALAD only at 12 months before HCC diagnosis at 10% FPR and when over time gradients in AFP, AFP L3, and DCP are available. Impact and implications Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with early detection being critical for improving survival outcomes. This study provides a rigorous phase 3 validation of the HES V2.0 biomarker panel, demonstrating its superior or comparable sensitivity to established models like GALAD and ASAP in a large, diverse U.S. cirrhosis cohort. The findings are particularly impactful for clinicians and researchers focused on liver cancer surveillance, as HES V2.0 offers enhanced detection performance, especially when longitudinal biomarker data are available. These results support the integration of HES V2.0 into clinical workflows and future trials, potentially improving early HCC detection and enabling timely curative interventions for at-risk patients. |
| Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
Lenvatinib demonstrated promising efficacy and a manageable safety profile as a second-line treatment for patients with HCC progressing on atezo-bev. These findings offer prospective evidence supporting lenvatinib as a viable treatment option in the post-atezo-bev context. Impact and implications This study provides the first prospective evidence for the use of lenvatinib as a second-line therapy for patients with unresectable hepatocellular carcinoma who have progressed after first-line atezo-bev treatment. The findings highlight the potential of lenvatinib as a viable therapeutic option in a clinical setting where few alternatives are available. The results are particularly important for healthcare professionals managing unresectable hepatocellular carcinoma, as they provide a robust framework for considering lenvatinib in second-line treatment protocols. Given the manageable safety profile, these findings could be translated into practical recommendations for clinical practice, offering physicians a treatment strategy to improve patient outcomes following atezo-bev failure while guiding future research into combination therapies and broader patient populations. Clinical trial number NCT06138769. |
| Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
Discordance between LSM and biochemical response is frequent. Most recent or current LSM is the strongest predictor of first liver-related events in patients with PBC, irrespective of prior biochemical response or LSM trajectory. Impact and implications Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the clinical relevance and how discordant biochemical and LSM changes should be best interpreted remain unclear. In this large international multicenter study, we demonstrated that once the current LSM (LSMc) is known, prior LSM trajectories and biochemical changes did not improve the prediction of liver-related events in patients with PBC. |
| Reversal of ACLF and ALF using whole blood extracorporeal system combining HLA-depleted liver organoids with granulocyte-monocyte apheresis.
The tandem UTOpiA circuit provides a significant survival benefit in preclinical rodent models of ACLF and ALF by providing anti-inflammatory, synthetic, and metabolic support. Understanding the regenerative signals that promote recovery of the injured liver will broaden the scope of this whole blood extracorporeal system, potentially serving as a new off-the-shelf liver support therapy. Impact and implications Restoring hepatic metabolism while controlling inflammation in acutely decompensated cirrhosis, is a major clinical unmet need. Combining human HLA-modified human iPSC derived liver organoids with granulocyte and monocyte apheresis, we report a bioartificial liver system to manage inflammation, restore liver function and augment regenerqation in two rat models of severe liver failure. This therapy could offer a off-the-shelf therapeutic option for patients with life-threatening liver failure. |
| Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma.
Tumor cell-state plasticity driven by the FOXM1/CEBPB axis induces developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma. RNAi-based therapies targeting hepatic FOXM1 showed strong potential for further clinical testing. Impact and implications Tumor heterogeneity and therapeutic resistance remain major barriers in cancer treatment, largely driven by dynamic transitions across multiple cellular states. This study reveals that the FOXM1/CEBPB axis is a crucial regulator of these hierarchical cellular transitions and plays a key role in sustaining developmental heterogeneity and promoting resistance to therapies. By targeting this axis, we demonstrated the restoration of developmental homogeneity and significant disruption of therapeutic resistance in preclinical models. Furthermore, our findings highlight the strong efficacy of RNAi-based therapeutics directed at hepatic FOXM1, highlighting their promising potential as pioneering small nucleic acid drugs for cancer therapy. |
| Transcriptomic and epigenetic mechanisms controlling cholangiocytes transdifferentiation into hepatocytes.
Overall, our results confirm that cholangiocytes can transdifferentiate into hepatocytes. This process is promoted by HNF4G, it involves epigenetic remodelling, and is consistent across the three liver lobes. This knowledge paves the way for future therapies aiming to enhance liver regeneration by increasing cholangiocytes' plasticity. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Clin Gastroenterol Hepatol |
|---|
| Significance of Neoplasia Detection Rate in Barrett's Esophagus: A "PEEC" into the Data and Optimal Definitions. |
| Gastroenterology |
| Foundation Models in Medicine, Gastroenterology, and Endoscopy: The Next Frontier? |
| In Memoriam: Jaume Bosch, MD, PhD. |
| Gut |
| Current and emerging concepts for systemic treatment of metastatic colorectal cancer.
These findings open new avenues for the development of advanced immunotherapies for CRC. In this review, we summarise major developments in the systemic therapy of CRC within the last couple of decades, provide an overview of emerging and soon-to-be implemented therapeutic strategies and present concepts from clinical and preclinical research to manipulate tumour cells and the tumour stroma to sensitise microsatellite stable colorectal tumours to immunotherapy. |
| Rise of precision medicine: can it deliver on its promise in IBD?
In this concept, longitudinal assessment of patient-reported outcomes and molecular profiling in response to therapy may serve as early predictors of long-term outcomes, guide early therapeutic adjustments and reveal mechanisms that open new therapeutic avenues, such as adjunct or combination treatments. Adopting this dynamic, data-driven approach to treatment adaptation could shift management of IBD from reactive to proactive and substantially improve long-term outcomes with the vision to fully control a life-long disease. |
| J Hepatol |
| Postnatal hepatocyte proliferation - challenge and opportunity for gene therapy. |
| Rat hepatitis E virus: An emerging challenge in human hepatitis. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| "Functional" GI Conditions in the Older Adult: DGBIs and Beyond. |
| 2025 CME Information. |
| American College of Gastroenterology Monograph on Geriatrics and GI. |
| Calendar of Courses, Symposiums and Conferences. |
| Colorectal Cancer Screening and Surveillance and Other Colon Conditions in the Older Adult. |
| Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults. |
| Editor and Author Profiles. |
| Gastro-Esophageal Disorders of the Geriatric Population. |
| How I Approach Flatulence. |
| Letter to the Editor. |
| Letter to the Editor. |
| Monograph Conclusion. |
| Pancreatic Cysts and Pancreatitis in the Older Adult. |
| Practical Advice for the Management of Older Adults With Inflammatory Bowel Disease. |
| Rallentando un Poco : Carvedilol and Its Role in Cirrhosis Progression. |
| Response to Biswas et al. |
| Response to Tan et al. |
| The Illusion of Response: Diffuse Hepatic Metastasis Masked by Shrinking Lesions in Neuroendocrine Carcinoma of the Cervix. |
| Vaccination Outcomes and Recommendations Among Older Adults in a Gastroenterology and Hepatology Practice. |
| Clin Gastroenterol Hepatol |
| High Prevalence of Difficult Readability of Gluten-Free Diet Recommendations for Celiac Disease Patients. |
| Syphilitic Proctitis Mimicking Ulcerative Colitis. |
| Endoscopy |
| A novel slim cholangioscope facilitates antegrade laser lithotripsy for an intrahepatic biliary stone with acute ductal angulation. |
| Artificial intelligence for colorectal polyp sizing: clinical promise and methodological challenges. |
| Circumferential long-segment Barrett's esophagus fully involved by adenocarcinoma resected by endoscopic submucosal dissection. |
| Endoscopic full-thickness defect closure using a novel suture anchor device: a pilot survival porcine study. |
| Endoscopic hand-suturing for endoscopic submucosal dissection wound closure: a didactic clinical case presentation. |
| Endoscopic submucosal dissection of a large cavernous hemangioma in the proximal esophagus. |
| Endoscopic ultrasound-guided radiofrequency ablation for a pancreatic insulinoma: a novel endoscopic management strategy. |
| Micro-endoscopic retrograde cholangiopancreatography catheter-assisted endoscopic laser lithotripsy: improving insertability and safety. |
| Mucosal zipper endoscopic resection offers a novel option for the treatment of gastric submucosal tumors. |
| Pitfall of endoscopic ultrasound-guided hepaticoduodenostomy: Impact of hepatic parenchymal volume during device insertion. |
| Pitfalls of endoscopic ultrasound-guided gallbladder drainage using a lumen-apposing metal stent: impact of the intraluminal water-filling technique. |
| Snare traction-assisted ultra-long tunnel endoscopic resection of a giant exophytic cardia subepithelial tumor with diaphragmatic adherence. |
| Submucosal tunneling endoscopic resection for the treatment of infantile gastric duplication cyst: the first report in infants. |
| Troubleshooting guidewire perforation of the bile duct during endoscopic ultrasound-guided hepaticogastrostomy using the liver impaction technique. |
| Underwater endoscopic submucosal dissection via continuous irrigation method and red dichromatic imaging for a rectal cancer with severe fibrosis. |
| Gastroenterology |
| From Ongoing Fibrosis to Biopsy to Diagnosis: A Thorough Evaluation of Liver Granulomas in Clinical Practice. |
| Learning to Tolerate: Searching for the Cells Responsible for Food Antigen Tolerance. |
| Mass screening of celiac disease: a crossing point between secondary and primary prevention? |
| Gut |
| Biology of regional gut-mucosal-transcriptomes in healthy individuals and individuals with diabetic: incorporating cellular composition and embracing variation. |
| FODMAPs and functional dyspepsia: emerging evidence but unanswered questions. |
| ISG15-CREB1 ISGylation: a stellate cell brake in liver fibrosis. |
| Hepatology |
| Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder. |
| Letter to the Editor: Clarifying LSM cutoff validation, statistical power, and subgroup applicability in predicting liver-related events in chronic hepatitis B. |
| Letter to the Editor: Dropout dynamics in RT+LT vs LR for pCCA-an overlooked variable? |
| Multi-omics and machine learning in cholangiocarcinoma: A paradigm shift toward molecular subtyping and precision therapy. |
| Re: Are we overestimating LSM-Based HCC risk in MASLD? Addressing immortal time bias. |
| Reply: Clarifying LSM cutoff validation, statistical power, and subgroup applicability in predicting liver- related events in chronic hepatitis B. |
| The Liver Meeting: 2025 Abstracts. |
| The Liver Meeting: 2025 Subject Categories. |
| J Hepatol |
| FGF21 and the brain-liver axis: Harnessing sympathetic pathways in MASH. |
| Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Letter on "Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas-Sensing Wireless Motility Capsules". |
| Letter on 'Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas-Sensing Wireless Motility Capsules': Authors' Reply. |
| Clin Gastroenterol Hepatol |
| Letter to the Editor re: The Assessment of Gastrointestinal Transit by the Atmo Capsule: A Comparison With the SmartPill Capsule. |
| Endosc Int Open |
| Urgency for standardized protocols to improve clinical implementation of artificial intelligence in endoscopic diagnostics. |
| Gastroenterology |
| Cautious Implementation of Helicobacter pylori Eradication in the Elderly. |
| Comments on "Preventive effect of Helicobacter pylori treatment on gastric cancer incidence and mortality: A Korean population study". |
| Methodological Considerations in Evaluating the Preventive Effect of Helicobacter pylori Eradication on Gastric Cancer Incidence and Mortality. |
| Reassessing the Observational Evidence for H. pylori Eradication and Gastric Cancer Prevention. |
| Revisiting gender differences in gastric cancer prevention with Helicobacter pylori eradication therapy. |
| Translating Population-Based Evidence on H. pylori Eradication into Precision Surveillance Strategies. |
| Gut |
| EUS-guided portal pressure measurement: how to make it more accurate? Authors' response. |
| Impaired glucose metabolism in irritable bowel syndrome: personalised low-glycaemic diet as potential therapeutic target. |
| Improving evidence, but at what ethical price? |
| Response to 'Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?' |
| Response to Abdulrahman Qatomah <i>et al</i> and Suchanart Jitrukthai <i>et al</i>. |
| Response to: 'Differentiating gastroparesis from functional dyspepsia is no longer sufficient' by O'Grady <i>et al</i>. |